Search 

PCS provides new product engineering and design services for medical device and Medtech companies. We have served enterprise and entrepreneurs for over two decades and our QMS is ISO13485:2016 certified.

The Top 10 Big Chinese Pharmaceuticals focusing on Oncology and other therapeutic area with unmet needs.

We are working with life sciences companies to access China, which typically includes setting up, managing and funding local entities and/or finding local partners, investors and other resources. -;Current focus on cannabis/hemp, diagnostics, digital health.

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.

Respinova has developed a new device for the treatment of COPD a group of progressive, debilitating respiratory conditions, including emphysema and chronic bronchitis. COPD is the third leading cause of death. Worldwide there are over 350 million with 50 million in China.
Respinova’s Pulsehaler™ technology is the first and only treatment to directly re-open the collapsed small airways of COPD patients, thereby reducing breathlessness and improving patient’s ability to walk. The technology was clinically proven in a clinical study, and published in the peer reviewed Journal of COPD. Our technology is protected by 6 patent families, with 15 issued patents and many additional pending patents.
Respinova’s technology pipeline also includes devices for improving delivery of inhaled drugs. This technology was clinically proven to deliver drugs more than 200% better than traditional nebulizers, with significant improvements in lung function. We have begun initial discussions with Pharma companies to partner in the development of Best-in-Class inhaled therapies, including COPD, Cystic Fibrosis, Asthma, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension.

Satya is an early-stage Oncology biotech focused on discovering small molecule NCEs, with novel targets against well-established Oncogenes, Tumor suppressors and Synthetic Lethal targets. Satya's team has over 50 years' combined discovery expertise, having worked on over 75 targets and delivered 15 clinical candidates

Selfit is a digital therapy startup focusing on the aging population and brain and heart conditions.
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.

Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.

Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,

SiGenex mission is to make clinical genetics accessible to everyone everywhere. The company is developing a bench top sample to answer targeted genetic testing solution that can be deployed anywhere in any resource setting environment.